ERBB2 and breast carcinoma: Background: While the prognosis is generally good for hormone receptor–positive (HR+), human epidermal growth factor–negative (HER2–) early breast cancer (EBC) patients, up to 30% of patients with high-risk clinical and/or pathologic features experience recurrence.